Affective switch is an important clinical issue when treating bipolar disorder. Though commonly seen in clinical practice, the benefits of prescribing antidepressants for bipolar depression are still controversial. To date, there have been few genetic studies and no genome-wide association study (GWAS), focusing on manic switch following bipolar depression. This study aims to investigate the effects of individual genomics and antidepressant medication on the risk of manic switch in bipolar I disorder (BPI). A total of 1004 patients with BPI who had at least one depressive episode with complete data on antidepressant treatment and outcome were included. Clinical assessment of mania and depression was performed by trained psychiatric nurses and psychiatrists using the Chinese version of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN), and the diagnosis of BPI was made according to DSM-IV criteria. Manic switch was defined as a manic episode occurring within eight weeks of remission from an acute depressive episode. The age at first depressive episode of the study patients was 30.7 years (SD 12.5) and 56% of all patients were female. GWAS was carried out in a discovery group of 746 patients, followed by replication in an independent group of 255 patients. The top SNP rs10262219 on chromosome 7 showed the strongest allelic association with manic switch (p = 2.21 × 10−7) in GWAS, which was however not significantly replicated. Antidepressant treatment significantly (odds ratio 1.7; 95% CI 1.3−2.2; p < 0.001) increased the risk of manic switch. In logistic regression analysis, the CC genotype of rs10262219 (odds ratio 3.0; 95% CI 1.7−5.2) and antidepressant treatment (odds ratio 2.3; 95% CI 1.4−3.7) significantly increased the risk of manic switch with a joint effect (odds ratio 5.9; 95% CI 3.7−9.4). In conclusion, antidepressant medication and rs10262219 variants jointly increased the risk of manic switch after bipolar depression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033004PMC
http://dx.doi.org/10.3390/jpm12040615DOI Listing

Publication Analysis

Top Keywords

manic switch
32
antidepressant treatment
16
switch bipolar
16
risk manic
16
odds ratio
16
ratio 95%
16
bipolar disorder
12
bipolar depression
12
depressive episode
12
increased risk
12

Similar Publications

Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.

J Affect Disord

December 2024

Louis A. Faillace Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center at Houston, 1941 East Rd, Houston, TX 77054, USA. Electronic address:

Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other mental health problems. However, individuals with bipolar disorder (BD) have been excluded from most clinical trials due to concerns about manic switches or psychosis. This study aimed to systematically examine the effects of recreational psychedelic use in individuals with BD.

View Article and Find Full Text PDF
Article Synopsis
  • The study researched the optimal dose of lurasidone for treating bipolar depression, focusing on efficacy, acceptability, and metabolic/endocrine effects.
  • It reviewed five clinical trials involving 2,032 patients and found that doses between 40-60 mg significantly improved depression, anxiety, and quality of life while experiencing manageable side effects.
  • Results indicated that while higher doses led to increased side effects and weight gain, a 40-60 mg dose was generally the best choice for treatment without major risks of dropout or manic switch.
View Article and Find Full Text PDF

Responses to clinical treatment of bipolar versus unipolar depressive episodes in women versus men.

J Psychopharmacol

November 2024

International Consortium for Mood and Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Belmont, MA, USA.

Background: Whether responses to treatment of major depressive episodes differ between women and men or with bipolar (BD) and major depressive disorders (MDD) remains unresolved.

Aims: To test for diagnostic and sex differences in responses to treatment of depression.

Methods: We compared changes in the 21-item Hamilton Depression Rating Scale (HDRS) ratings of depression ( = 3243) between women (64.

View Article and Find Full Text PDF

Bipolar disorder represents a significant source of morbidity and elevated mortality risk. Ketamine has emerged as a powerful antidepressant; however, there have been few trials of ketamine in bipolar depression and no trials with esketamine in bipolar depression, and few data exist from real-world settings. Here, we report outcomes from a cohort of patients with bipolar depression treated with ketamine/ esketamine in a real-world setting.

View Article and Find Full Text PDF

Introduction: Patients with bipolar I disorder may experience mood destabilization or treatment-emergent affective switch (TEAS) from one symptom pole to the other spontaneously or following treatment. Optimal treatment should address symptoms from both poles without precipitating destabilization.

Methods: These were pooled post hoc analyses of data from randomized, double-blind, placebo-controlled studies of cariprazine 3-12 mg/d for bipolar I mania (NCT00488618, NCT01058096, NCT01058668) and cariprazine 1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!